197 related articles for article (PubMed ID: 308512)
1. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.
Counts RB; Paskell SL; Elgee SK
J Clin Invest; 1978 Sep; 62(3):702-9. PubMed ID: 308512
[TBL] [Abstract][Full Text] [Related]
2. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.
Switzer ME; McKee PA
J Clin Invest; 1976 Apr; 57(4):925-37. PubMed ID: 1084890
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand activity of low molecular weight human Factor VIII increases by binding to gold granules.
Furlan M; Perret BA; Beck EA
Thromb Haemost; 1981 Jun; 45(3):242-6. PubMed ID: 6792738
[TBL] [Abstract][Full Text] [Related]
4. Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.
Switzer ME; McKee PA
J Clin Invest; 1977 Oct; 60(4):819-28. PubMed ID: 408379
[TBL] [Abstract][Full Text] [Related]
5. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.
Ruggeri ZM; Zimmerman TS
J Clin Invest; 1980 Jun; 65(6):1318-25. PubMed ID: 6773982
[TBL] [Abstract][Full Text] [Related]
6. Purification of porcine and human ristocetin-Willebrand factor.
Olson JD; Brockway WJ; Fass DN; Bowie EJ; Mann KG
J Lab Clin Med; 1977 Jun; 89(6):1278-94. PubMed ID: 405441
[TBL] [Abstract][Full Text] [Related]
7. [Increased von Willebrand activity of low molecular-weight factor VIII following binding to gold granules].
Furlan M; Perret BA; Beck EA
Schweiz Med Wochenschr; 1980 Oct; 110(40):1456-8. PubMed ID: 6792697
[TBL] [Abstract][Full Text] [Related]
8. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.
Meyer D; Obert B; Pietu G; Lavergne JM; Zimmerman TS
J Lab Clin Med; 1980 Apr; 95(4):590-602. PubMed ID: 6965697
[TBL] [Abstract][Full Text] [Related]
9. Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.
Gralnick HR
J Clin Invest; 1978 Aug; 62(2):496-9. PubMed ID: 307560
[TBL] [Abstract][Full Text] [Related]
10. Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.
Vukovich TC
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):831-40. PubMed ID: 2436998
[TBL] [Abstract][Full Text] [Related]
11. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
Turecek PL; Siekmann J; Schwarz HP
Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
[TBL] [Abstract][Full Text] [Related]
12. Porcine Willebrand factor: a population of multimers.
Fass DN; Knutson GJ; Bowie EJ
J Lab Clin Med; 1978 Feb; 91(2):307-20. PubMed ID: 413873
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
14. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
Neugebauer BM; Goy C; Budek I; Seitz R
Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
[TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
17. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis.
Mazurier C; Samor B; Goudemand M
Thromb Haemost; 1986 Feb; 55(1):61-4. PubMed ID: 3486491
[TBL] [Abstract][Full Text] [Related]
18. Partial purification of biologically active, low molecular weight, human antihemophilic factor free of Von Willebrand factor. I. Partial characterization and evidence for disulfide bond(s) susceptible to limited reduction.
Harris RB; Newman J; Johnson AJ
Biochim Biophys Acta; 1981 May; 668(3):456-70. PubMed ID: 6786356
[TBL] [Abstract][Full Text] [Related]
19. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
Orthner CL
J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
[TBL] [Abstract][Full Text] [Related]
20. [Contribution to the isolation and study of the molecular weight of human factor VIII].
Mazurier C; Parquet-Gernez A; Goudemand M; Montreuil J
Pathol Biol (Paris); 1975 Dec; 23 suppl():11-6. PubMed ID: 57588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
